Skip to Main Content
Contact Us
Category: Next-generation therapies
Driving Innovation in Radiopharmaceutical Therapies Oncology clinical research is complex, demanding, and continually evolving. Bringing effective radiopharmaceutical therapies from proof-of-concept Read Now The Evolving Landscape of Oncology Drug Development Increasing incidence rates and the rise of novel therapies Oncology is the largest therapeutic area Read Now Breast cancer cells Developing Next-generation Therapies for Breast Cancer Patients Breast cancer is the second most common malignancy worldwide and the number one cancer in Read Now T-Cell Attacks Cancer Cell Helping to Develop Cell Therapies  Catalyst Oncology is a specialty oncology CRO devoting time, energy, and capital to supporting biotechs Read Now Antibody drug conjugates with blue cells Helping to Bring Antibody Drug Conjugates (ADCs) to Patients  Catalyst Oncology is a specialty oncology contract research organization (CRO) devoting time, energy, and capital Read Now Helping to Bring Cancer Therapies to Patients  Niche CRO with a difference Catalyst Oncology is a niche oncology CRO devoting time, energy, Read Now Helping to Bring Immunotherapies to Cancer Patients in Need Catalyst Oncology is a specialty oncology clinical research organization (CRO) devoting time, energy, and capital Read Now Helping to Bring Hematologic Oncology Therapies to Cancer Patients Catalyst Oncology is a niche oncology clinical research organization (CRO) devoting time, energy, and capital Read Now Catalyst Clinical Research, Ledger Run Expand Strategic Partnership To Accelerate Research, Streamline Clinical Operations Catalyst Streamlines Business Processes with New Technologies Wilmington, NC and Tiburon, CA – 8 February Read Now Activate CRO Partnership Program Calyx Welcomes Catalyst to the ACTIVATE CRO Partnership Program Synergistic offerings deliver successful early phase oncology clinical trials Nottingham, UK – May 10, 2021 Read Now